@FierceBiotech: Is Bristol-Myers fading back in its hot race with Merck for PD-1 lead? More | Follow @FierceBiotech
@JohnCFierce: Scoff warning: This buyout story relates to experimental dendritic cell cancer vaccine tech. Story | Follow @JohnCFierce
@DamianFierce: ICYMI: Big-time pharma contractor Catalent lines up for an IPO worth $100M--or much more. Article | Follow @DamianFierce
@EmilyMFierce: Study: mutations in Russian TB strain make it drug-resistant. Story via Wired UK | Follow @EmilyMFierce
> Just weeks after seeing its share price rocket up on news of a Celgene milestone payment, Epizyme ($EPZM) is looking to raise $140 million through the sale of stock for its development work in epigenetics. Filing
> Chelsea Therapeutics, which has gone through a number of ups and downs in its development of Northera, named Joseph Oliveto as the biotech's permanent CEO. Story
> Celsion ($CLSN) says the latest overall survival data from its post-hoc analysis of results from its Phase III HEAT study of ThermoDox supports continued clinical development. Release
@FierceMedDev: U.K. researchers unveil an artificial pancreas they've been developing for 20 years. News | Follow @FierceMedDev
@MichaelGFierce: St. Jude places its first Nanostim leadless pacemaker in a U.K. patient. Story | Follow @MichaelGFierce
@EmilyWFierce: Johnson & Johnson's Animas launches new combination insulin pump in Canada. Article | Follow @EmilyWFierce
@GalenMoore: Pfizer misses its endpoint for 2 PhIII trials of dacomitinib in non-small cell lung cancer. Release | Follow @GalenMoore
> 23andMe's genome test raises more questions, this time for ancestry results. Item
> Varian, Toshiba announce a $515M medical imaging deal. More
> Edwards nabs EU nod for next-gen Sapien as competition mounts. News
Pharma News
@FiercePharma: Merck KGaA CFO jumps ship amid turnaround he helped engineer; shares slide. Story | Follow @FiercePharma
@TracyStaton: Q4 sales up, 2013 down, esp in US: Bristol-Myers Squibb Reports 4th Quarter and Full Year 2013 Results. Release | Follow @TracyStaton
@EricPFierce: Ranbaxy will need new markets as FDA closes window on U.S., analysts predict. Piece | Follow @EricPFierce
@CarlyHFierce: Bristol-Myers impresses with trimmed-down costs, pumped-up sales. Story | Follow @CarlyHFierce
> Merck KGaA CFO jumps ship amid turnaround he helped engineer; shares slide. Story
> Spurred by pricey Gilead hep C drug, payers cook up new cost-control moves. Article
> Pfizer weighs legal options as PA Supreme Court revives Redux design-defect suit. News
> Ranbaxy will need new markets as FDA closes window on U.S., analysts predict. More
CRO News
> Report: Indian clinical trials fell 93% last year. Story
> CRO Genae reaches into Germany for device trials. News
> ResearchDx pushes into the Middle East for diagnostics development. Article
> Catalent lines up for an IPO worth $100M--or much more. More
> Covance adding 500 jobs in U.K. nutrition expansion. Piece
> Datatrak, Clinverse team up for clinical trial tech. Item
Biotech IT News
> The clinical trial technology sector could top $5B by 2018, report says. Story
> Sony teams with Illumina to crack the Japanese genome market. More
> Report: Pharma is missing a Big Data opportunity by ignoring social media. News
> The NCI is offering $20M to pilot projects that move cancer genomics into the cloud. Piece
> U.K. to digitize patient health records and sell access to biopharma researchers. Article
> Novo Nordisk taps Trialbee for online recruitment of trial patients. Item